Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 30, 2016
Pharmacy Choice - News - Generic Drugs - July 30, 2016

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 73     Next >>     Go To Page:

7/30/16 - Fosun buys Indian pharma company [China Daily: Africa Weekly]
A view of Fosun Group signage in Shanghai. Shanghai Fosun Pharmaceutical Co Ltd announced that it will acquire an 86.08 percent stake in Indian pharmaceutical enterprise Gland Pharma Ltd for $1.26 billion, in the largest overseas acquisition by a Chinese pharmaceutical company. Gland Pharma, one of world's largest providers of injectable generic...
7/29/16 - Ajanta Pharma ends 3% higher on FDA nod [India Infoline News Service]
Shares of Ajanta Pharma closed 3% higher at Rs.1, 777.20 on BSE after the company announced that it has received USFDA nod for oral suspension drug. The company announced the receipt of final approval for Omeprazole and Sodium Bicarbonate Powder for Oral Suspension from US FDA. In total, Ajanta has 26 Abbreviated New Drug Application of which it ha
7/29/16 - Ajanta Pharma gets USFDA nod for generic acid reflux drug [Daily Star, The (Lebanon)]
Ajanta Pharma has received approval from the US health regulator for generic Omeprazole and sodium bicarbonate powder for oral suspension used for the treatment of stomach and esophagus problems such as ulcers and acid reflux. The company has received approval from the United States Food and Drug Administration for the same and will soon be launchi
7/29/16 - Centre to make prescription for generic medicines mandatory [UMCI News]
Minister for Chemicals and Pharmaceuticals Ananth Kumar told Rajya Sabha on Thursday that the Centre is trying to make prescription of generic name of a medicine mandatory by amending the Medical Council Act. This measure will help a number of poor patients, Ananth Kumar said while replying to a calling attention motion on the high prices of essent
7/29/16 - Cipla, Aurobindo Pharma acquire products divested by Teva in US [Arab News (Saudi Arabia)]
Cipla Ltd, Indias fifth largest drug maker, on Thursday announced that it has acquired a portfolio of three products from Teva Pharmaceutical Industries Ltd in the US, which are being divested by the Israel- based company as a precondition to its $40.5 billion acquisition of Allergan Plcs generic business. The spokesperson for Cipla confirmed the p
7/29/16 - Fosun buys Gland Pharma for $1.3bn [Palestine Chronicle, The]
Gland Pharma, which manufactures generic injectable pharmaceutical products, on Friday announced that Shanghai Fosun Pharmaceutical Group will acquire a majority 86% stake in the company for a consideration of $1.26 billion. Fosun is a Chinese conglomerate with interests in businesses such as wealth management, healthcare and tourism, among others,
7/29/16 - FTC settlement confirms conditions of Teva-Allergan deal [Tripoli Post, The (Libya)]
The US Federal Trade Commission has approved Teva Pharmaceutical Industries takeover of the generics arm of Ireland- incorporated Allergan subject to the Israeli companys divestment of dozens of generic drugs. By selling off the drug portfolio, Teva, which is the largest generic pharmaceutical producer in the world, is settling FTC charges that its
7/29/16 - Indias Pharma King Earns Suffolk IDA Nod [Moj News Agency (Iran)]
The Suffolk County Industrial Development Agency on Thursday approved a corporate incentives package for Evaric Pharmaceutical, a generic drug-maker founded by Bandi Parthasaradhi Reddy, owner and chairman of global distributor Hetero, Indias largest privately held pharma. The sales and mortgage tax-abatement package allows Evaric Pharmaceutical...
7/29/16 - Pharmaceutical firm plans to open in Hauppauge [Khaleej Times (United Arab Emirates)]
Evaric Pharmaceutical, a new manufacturer of generic drugs, plans to open in Hauppauge in a space once occupied by Forest Laboratories. BPS Reddy is also a principal of Hetero, considered the largest private pharmaceutical company in India. Hetero has offices in 35 countries and employs 15,000, officials said.
7/29/16 - Teva Pharmaceutical Industries , Allergan Plc Win Us Antitrust Approval for Generics Deal: Fastenal Company , Logitech International , Lumentum Holdings [Daily Tribune (Bahrain)]
Teva Pharmaceutical Industries Limited has agreed to sell the rights and assets related to 79 pharmaceutical products to settle FTC charges that its proposed $40.5 billion acquisition of Allergan plcs generic pharmaceutical business would be anticompetitive. The FTC order will preserve competition in U.S. pharmaceutical markets where Teva and...
7/29/16 - Teva will provide long-term API contracts to producers in 15 markets [Moj News Agency (Iran)]
The condition was made public when the FTC approved Teva Pharmaceutical`s $40.5 billion acquisition of Allergan`s generics portfolio on Wednesday. Since Teva will now own Allergan`s generics portfolio, the FTC argued in a public analysis, the company could squeeze out the Allergan generics competitors by raising the supply price of its APIs.
7/28/16 - Animal Generic Drug User Fee Rates and Payment Procedures for Fiscal Year 2017
The Federal Food, Drug, and Cosmetic Act, as amended by the Animal Generic Drug User Fee Amendments of 2013, authorizes FDA to collect user fees for certain abbreviated applications for generic new animal drugs, for certain generic new animal drug products, and for certain sponsors of such abbreviated applications for generic new animal drugs and/o
7/28/16 - AstraZeneca says 2Q earnings fell 22 per cent
LONDON Anglo-Swedish drugmaker AstraZeneca says second-quarter earnings fell 22 per cent after sales of its blockbuster cholesterol drug Crestor dropped sharply after a generic alternative came on the market in the United States.
7/28/16 - AstraZeneca says 2Q earnings fell 22 percent
Anglo-Swedish drugmaker AstraZeneca says second-quarter earnings fell 22 percent after sales of its blockbuster cholesterol drug Crestor dropped sharply after a generic alternative came on the market in the United States. Core operating profit, which excludes one-time items such as restructuring costs and impairments, dropped to $1.41 billion fr
7/28/16 - Biosimilar User Fee Rates for Fiscal Year 2017
The Federal Food, Drug, and Cosmetic Act, as amended by the Biosimilar User Fee Act of 2012, authorizes FDA to assess and collect user fees for certain activities in connection with biosimilar biological product development, certain applications and supplements for approval of biosimilar biological products, establishments where approved biosimilar
7/28/16 - FDA Announces Animal Generic Drug User Fee Rates, Payment Procedures for Fiscal 2017
WASHINGTON, July 28 The Department of Health and Human Services published the following notice in the Federal Register from the Food and Drug Administration:. The Federal Food, Drug, and Cosmetic Act, as amended by the Animal Generic Drug User Fee Amendments of 2013, authorizes FDA to collect user fees for certain abbreviated applications for gen
7/28/16 - FDA Announces Biosimilar User Fee Rates for Fiscal 2017
WASHINGTON, July 28 The Department of Health and Human Services published the following notice in the Federal Register from the Food and Drug Administration:. Dates: No later than 5 calendar days after FDA grants the sponsor's request for a BPD meeting for that product, or upon the date of submission of an IND describing an investigation that FDA
7/28/16 - Fosun Pharma To Acquire Approx. 86% Stake In Gland; KKR To Divest Its Full Stake
WASHINGTON- Gland Pharma Limited, an Indian pure-play generic injectable pharmaceutical products company, announced a definitive agreement under which Shanghai Fosun Pharmaceutical Co. Ltd., a Chinese health care provider, will acquire an approximate 86% stake in Gland for up to $1.26 billion. Fosun Pharma will purchase all shares of Gland owned by
7/28/16 - Frontage Laboratories, Inc. Announces Formation of FJ Pharma, LLC, a Joint Venture with Zhejiang Jiuzhou Pharmaceutical Co, Ltd. to Provide API Development and Manufacturing Services [Palestine Chronicle, The]
Frontage Laboratories, Inc. announced that it has established a joint venture with Zhejiang Jiuzhou Pharmaceutical Co., Ltd. to provide enhanced access to high quality and economical API& intermediate development and manufacturing services to new US clients focused on New Chemical Entities and vertically-integrated generic APIs that are developed..
7/28/16 - Gland Pharma to be Acquired by Fosun Pharma
Gland Pharma Limited, a leading Indian pure-play generic injectable pharmaceutical products company, today announced the signing of a definitive agreement under which Shanghai Fosun Pharmaceutical Co. Ltd., a leading Chinese health care provider, will acquire an approximate 86% stake in Gland for up to US $1.26 billion. Ravi Penmetsa, will continue
7/28/16 - Glenmark ends in green; gets FDA nod for Potassium Chloride ER tablets [India Infoline News Service]
Glenmark Pharma ended 0.3% higher at Rs.853.05 on BSE after the company s parent company received FDA nod for new drug. Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Potassium Chloride Extended-Release Tablets USP, 10 mEq and 20 mEq, the generic version of K-Dur Extended-Rel
7/28/16 - Hemispherx Biopharma Reaches Agreement with Avrio Biopharmaceuticals for the Accelerated Production of Ampligen [Khaleej Times (United Arab Emirates)]
-Hemispherx Biopharma announced today that it has reached an agreement with Avrio Biopharmaceuticals, Irvine California, to serve as an additional contract manufacturer of Hemispherxs experimental drug, Ampligen, also known by its generic name rintatolimod. Avrio, an FDA inspected facility, has the capabilities for the compounding and fill/finish o
7/28/16 - JAZZ PHARMACEUTICALS PLC FILES (8-K) Disclosing Other Events
In November 2010, Jazz Pharmaceuticals, Inc., a wholly owned subsidiary of the Company, filed a lawsuit in the United States District Court for the District of New Jersey against Roxane Laboratories, Inc. seeking a permanent injunction to prevent Roxane from introducing a generic version of Xyrem that would infringe the Company's patents.
7/28/16 - Korea Kolmar to supply generic CNS treatment to Abbott [Tripoli Post, The (Libya)]
Korea Kolmar has signed an agreement with Abbott Korea for the exclusive supply of drugs, it announced on July 27. The domestic market for pregabalin, known to be effective for reducing central neuropathic pain, is estimated to be 43 billion won. And when Pfizers patent for the use of pregabalin in the neuropathic pain in adults, branded under Lyri
7/28/16 - Korean biosimilar drugs lift European market share [Korea Times]
Biogen, a U.S. multinational biotechnology company, announced its second-quarter results last Friday, including the sales records of Benepali, an arthritis drug developed by Samsung Bioepis and marketed by it in Europe. Samsung Bioepis has been making Benepali, its first biosimilar product, in Biogen's factory in Denmark. Sales of Inflectra, a rheu
Articles(s): 1 - 25 of 73     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415